Natera

Veracyte

Bio-Techne

Agilent Technologies

Beam Therapeutics

Arrowhead Pharmaceuticals

Illumina

BioMarin Pharmaceutical

Sarepta Therapeutics

CRISPR Therapeutics

Global X Genomics & Biotechnology ETF

GNOM tracks an index of global biotech equities, selected and weighted by market cap.

GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future.

GNOM: Poor Historical Performance, Lack Of Focus, Uncertain Future

ARK Genomic Revolution Multi-Sector ETF

iShares Genomics Immunology and Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Wisdomtree BioRevolution Fund

These ETFs give you exposure to CRISPR gene editing without having to pick individual stocks.

Top ETFs Tracking CRISPR Gene Editing

Global X Artificial Intelligence & Technology ETF

ARK Innovation ETF

ARK Industrial Innovation ETF

ARK Web x.0 ETF

Global X Blockchain ETF

Global X Robotics & Artificial Intelligence ETF

iShares Cloud 5G and Tech ETF

iShares Robotics & Artificial Intelligence Multisector ETF

First Trust Indxx Innovative Transaction & Process ETF

The 3D Printing ETF

ROBO Global Robotics and Automation ETF

Simplify Volt RoboCar Disruption and Tech ETF

Investment strategies geared to the future evaluate complex dynamics that can evolve rapidly. As innovation's market share has grown, investment capacity - as measured by average days to trade - also has improved significantly.

Equity Market Cap For Technologically Enabled Innovation Likely To Grow Exponentially

Join us for a triple-header to determine the best genomics biotech ETF!

ETF Battles: ARKG Vs IDNA Vs GNOM

Global X Genomics & Biotechnology ETF is a passive ETF with a healthcare sector focus.

Global X Genomics & Biotechnology ETF: Targeted Fund Provides Strong Growth And Steady Dividend

Amplify Treatments Testing & Advancements ETF

iShares U.S. Pharmaceuticals ETF

Pacer BioThreat ETF

SPDR S&P Health Care Equipment ETF

The Biden administration recently offered a $65 billion plan that U.S. officials say is aimed at combating the biological threats after the COVID-19 pandemic goes away.

Healthcare ETFs to Gain on $65-Billion Pandemic Protection Plan

Editas Medicine

Intellia Therapeutics

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

How Are Genomics ETFs Responding to Q2 Earnings?

ETF investors looking to get in on the next generation of medical technology may want to give the Global X Genomics & Biotechnology ETF (GNOM) a closer look. Genomic sequencing is already playing a pivotal role in combating Covid-19.

Snag Next-Generation Tech Exposure with This Genomics ETF

The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.

Genomics ETFs Surge on a Major Breakthrough in CRISPR Study

Alerian MLP ETF

InfraCap MLP

Breakwave Dry Bulk Shipping ETF

Principal Healthcare Innovators Index ETF

Global X Cybersecurity ETF

These four ETF areas were winners last week.

4 ETF Areas Surged Last Week

Biogen

Clover Health Investments

First Trust NYSE Arca Biotechnology Index Fund

Orphazyme A/S

ALPS Medical Breakthroughs ETF

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

Top-Performing Biotech ETFs of Last Week

iShares MSCI India ETF

SPDR S&P Biotech ETF

In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing.

3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort

Annovis Bio

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

abrdn Life Sciences Investors 

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Prothena

Cassava Sciences Inc

Supernus Pharmaceuticals

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

Which biotech/genomics ETF is the better play?

ETF Battles: ARKG Vs GNOM

Direxion Daily Healthcare Bull 3x Shares

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

abrdn Healthcare Investors 

iShares U.S. Healthcare ETF

John Hancock Multifactor Healthcare ETF

Global X Longevity Thematic ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

ProShares UltraShort Health Care

ProShares Ultra Health Care

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

SPDR S&P Pharmaceuticals ETF

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

Biotech Innovations Remain At Forefront

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

Genomics could be the next big thing in the biotechnology space. Similarly, the Global X Genomics & Biotechnology ETF (GNOM) could be the next big fund, and is already up 10% to start the new year.

Can Global X's GNOM Be the Next Big ETF?

The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.

Top-Performing Biotech ETFs Amid the COVID-19 Crisis

It's one thing to discuss the economics of investing in the biotech sector, but it's another to discuss genomics. The sub-sector of the biotech industry has seen strong growth as evidenced by the over 60% gain year-to-date for the Global X Genomics & Biotechnology ETF (GNOM), according to Morningstar performance numbers.

Get On Board a Growing Biotech Industry With the GNOM ETF

Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4% by the afternoon, while the Defiance Nasdaq Junior Biotechnology ETF and the SPDR S&P Biotech ETF both gained 3.5%.

Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up

Genomics ETFs have surged of late; here's why

Why You Should Invest in Genomics ETFs

Invesco Solar ETF

AXS Cannabis ETF

SPDR S&P Semiconductor ETF

Last week was cheery for Wall Street, with the S&P 500 and Nasdaq recording their best weekly advancement since July.

Top Sector ETFs From Wall Street's Best Week in 3 Months

The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.

Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers

Roundhill Sports Betting & iGaming ETF

Global X Telemedicine & Digital Health ETF

iShares Global Clean Energy ETF

iShares U.S. Oil Equipment & Services ETF

The recent market rout led by the tech selloff has provided investors a great opportunity to tap the stocks under $20.

Buy the Dip With These ETFs Under $20

News for Global X Genomics & Biotechnology ETF ETF (GNOM)